Neuroimaging allows researchers and clinicians to noninvasively assess structure and function of the brain. With the advances of imaging modalities such as magnetic resonance, nuclear, and optical imaging; the design of target-specific probes; and/or the introduction of reporter gene assays, these technologies are now capable of visualizing cellular and molecular processes in vivo. Undoubtedly, the system biological character of molecular neuroimaging, which allows for the study of molecular events in the intact organism, will enhance our understanding of physiology and pathophysiology of the brain and improve our ability to diagnose and treat diseases more specifically. Technical/scientific challenges to be faced are the development of highly sensitive imaging modalities, the design of specific imaging probe molecules capable of penetrating the CNS and reporting on endogenous cellular and molecular processes, and the development of tools for extracting quantitative, biologically relevant information from imaging data. Today, molecular neuroimaging is still an experimental approach with limited clinical impact; this is expected to change within the next decade. This article provides an overview of molecular neuroimaging approaches with a focus on rodent studies documenting the exploratory state of the field. Concepts are illustrated by discussing applications related to the pathophysiology of Alzheimer’s disease.
AslundASigurdsonCJKlingstedtTGrathwohlSBolmontTDicksteinDL, and others. 2009. Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. Chem Biol4(8):673–84.
2.
AyazMBoikovASHaackeEMKidoDKKirschWM. 2010. Imaging cerebral microbleeds using susceptibility weighted imaging: one step toward detecting vascular dementia. J Magn Reson Imaging31(1):142–8.
3.
BadeaAJohnsonGAJankowskyJL. 2010. Remote sites of structural atrophy predict later amyloid formation in a mouse model of Alzheimer’s disease. Neuroimage50(2):416–27.
4.
BaltesCRadzwillNBosshardSMarekDRudinM. 2009. Micro MRI of the mouse brain using a novel 400 MHz cryogenic quadrature RF probe. NMR Biomed22(8):834–42.
5.
BergerCGremlichHUSchmidtPCannetCKneuerRHiestandP, and others. 2007. In vivo monitoring the fate of Cy5.5-Tat labeled T lymphocytes by quantitative near-infrared fluorescence imaging during acute brain inflammation in a rat model of experimental autoimmune encephalomyelitis. J Immunol Methods323(1):65–77.
6.
BergstromMGrahnenALangstromB. 2003. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol59(5–6):357–66.
BlinJBaronJCDuboisBCrouzelCFiorelliMAttar-LevyD, and others. 1993. Loss of brain 5-HT2 receptors in Alzheimer’s disease: in vivo assessment with positron emission tomography and [18F]setoperone. Brain116(Pt 3):497–510.
9.
BourayouRBoethHBenavHBetzTLindauerUNierhausT, and others. Fluorescence tomography technique optimized for noninvasive imaging of the mouse brain. J Biomed Opt2008;13(4):041311.
10.
BozzaliMCherubiniA. 2007. Diffusion tensor MRI to investigate dementias: a brief review. Mag Reson Imaging2007; 25(6):969–77.
11.
BraakmanNMatysikJvan DuinenSGVerbeekFSchliebsRde GrootHJ, and others. 2006. Longitudinal assessment of Alzheimer’s beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J Magn Reson Imaging24(3):530–6.
12.
BraakmanNvan BuchamMASchliebsRde GrootHJBAliaA. 2009. Recent advances in visualizing Alzheimer’s plaques by magnetic resonance imaging. Cur Med Imaging Rev5(1):2–9.
13.
BurgermeisterPCalhounMEWinklerDTJuckerM. 2000. Mechanisms of cerebrovascular amyloid deposition: lessons from mouse models. Ann N Y Acad Sci903:307–16.
14.
CagninABrooksDJKennedyAMGunnRNMyersRTrukheimerFE, and others. 2001. In vivo measurement of activated microglia in dementia. Lancet358(9280):461–7.
15.
ChamberlainRReyesDCurranGLMarjanskaMWengenackTMPodusloJF, and others. Comparison of amyloid plaque contrast generated by T2-weighted, T2*-weighted, and susceptibility-weighted imaging methods in transgenic mouse models of Alzheimer’s disease. Magn Reson Med2009; 61(5):1158–64.
16.
ContagCHStevensonDK. 2001. In vivo patterns of heme oxygenase-1 transcription. J Perinatol21Suppl 1:S119–24.
17.
Couillard-DespresSFinklRWinnerBPloetzSWiedermannDAignerR, and others. 2008. In vivo optical imaging of neurogenesis: watching new neurons in the intact brain. Mol Imaging7(1):28–34.
18.
DeCarliCFrisoniGBClarkCMHarveyDGrundmanMPetersenRC, and others; Alzheimer’s Disease Cooperative Study Group. 2007. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol64(1):108–15.
19.
DhenainMPrivatNDuyckaertsCJacobsRE. 2002. Senile plaques do not induce susceptibility effects in T2*-weighted MR microscopic images. NMR Biomed15(3):197–203.
20.
EnglerHForsbergAAlmkvistOBlomquistGLarssonESavitchevaI, and others. 2006. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain129(Pt 11):2856–66.
21.
FoersterT. 1948. Zwischenmolekulare Energiewanderung und Fluoreszenz. Ann Physik437(2):55–75.
22.
FrangioniJV. 2006. Translating in vivo diagnostics into clinical reality. Nat Biotech24(8):909–13.
23.
FrisoniGBFoxNCJackCRJrScheltensPThompsonPM. 2010. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol6(2):67–77.
24.
GambhirSS. 2004. Quantitative assay development for PET. In: PhelpsME, editor. PET—molecular imaging and its biological applications. New York: Springer. p 125–216.
25.
GoetzJIttnerLM. 2008. Animal models of Alzheimer’s disease and frontotemporal dementia. Nat Rev Neurosci9(7):532–44.
26.
GoosJDKesterMIBarkhofFKleinMBlankensteinMAScheltensP, and others. 2009. Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke40(11):3455–60.
27.
GoscheKMMortimerJASmithCDMarkesberyWRSnowdonDA. 2002. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology58(10):1476–82.
28.
HanyuHAsanoTSakuraiHImonYIwamotoTTakasakiM, and others. 1999. Diffusion-weighted and magnetization transfer imaging of the corpus callosum in Alzheimer’s disease. J Neurol Sci167(1):37–44.
29.
HanyuHSakuraiHIwamotoTTakasakiMShindoHAbeK. 1998. Diffusion-weighted MR imaging of the hippocampus and temporal white matter in Alzheimer’s disease. J Neurol Sci156(2):195–200.
HiguchiMIwataNMatsubaYSatoKSasamotoKSaidoTC. 2005. 19F and 1H MRI dectection of amyloid β plaques in vivo. Nat Neurosci8(4):527–33.
33.
HintersteinerMEnzAFreyPJatonALKinzyWKneuerR, and others. 2005. In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotech23(5):577–83.
34.
HydeDde KleineRMacLaurinSAMillerEBrooksDHKruckerT, and others. 2009. Hybrid FMT-CT imaging of amyloid-beta plaques in a murine Alzheimer’s disease model. Neuroimage44(4):1304–11.
35.
IadecolaC. 2004. Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat Rev Neurosci5(5):347–60.
36.
IkonomovicMDKlunkWEAbrahamsonEEMathisCAPriceJCTsopelasND, and others. 2008. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. 131(Pt 6):1630–45.
37.
JackCRJrLoweVJWeigandSDWisteHJSenjemMLKnopmanDS, and others; Alzheimer’s Disease Neuroimaging Initiative. 2009. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain132(Pt 5):1355–65.
38.
JagustWJFriedlandRPBudingerTFKossEOberB. 1988. Longitudinal studies of regional cerebral metabolism in Alzheimer’s disease. Neurology38(6):909–12.
39.
JudenhoferMSWehrlHFNewportDFCatanaCSiegelSBBeckerM, and others. 2008. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 14(4):459–65.
40.
KadirADarreh-ShoriTAlmkvistOWallAGrutMStrandbergB, and others. 2008. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging29(8):1204–17.
41.
KemppainenNLaineMLaaksoMPKaasinenVNagrenKVahlbergT, and others. 2003. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer’s disease. Eur J Neurosci18(1):149–54.
42.
KemppainenNRuottinenHNagrenKRinneJO. 2000. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology25;55(2):205–9.
43.
KepeVBarrioJRHuangSCErcoliLSiddarthPShoghi-JadidK, and others. 2006. Serotonin 1A receptors in the living brain of Alzheimer’s disease patients. Proc Natl Acad Sci U S A103(3):702–7.
44.
KinoshitaMMcDannoldNJoleszFAHynynenK. 2006. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun340(4):1085–90.
45.
KlohsJGraefeMGrafKSteinbrinkJDietrichTStibenzD, and others. 2008a. In vivo imaging of the inflammatory receptor CD40 after cerebral ischemia using a fluorescent antibody. Stroke39(10):2845–52.
46.
KlohsJSteinbrinkJBourayouRMuellerSCordellRLichaK, and others. 2009. Near-infrared fluorescence imaging with fluorescently labeled albumin: a novel method for non-invasive optical imaging of blood-brain barrier impairment after focal cerebral ischemia in mice. J Neurosci Methods180(1):126–32.
47.
KlohsJWunderALichaK. 2008b. Near-infrared fluorescent probes for imaging vascular pathophysiology. Basic Res Cardiol103(2):144–51.
48.
KlunkWELoprestiBJIkonomovicMDLefterovIMKoldamovaRPAbrahamsonEE, and others. 2005. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer’s disease brain but not in transgenic mouse brain. J Neurosci25(46):10598–606.
49.
KuhlDEKoeppeRAMinoshimaSSnyderSEFicaroEPFosterNL, and others. 1999. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease. Neurology52(4):691–9.
50.
LehmannSStiehlDPHonerMDominiettoMKeistRKotevicI, and others. 2009. Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events. Proc Natl Acad Sci U S A106(33):14004–9.
51.
LloydBSczcerbaDRudinMSzekelyG. 2008. A computational framework for modelling solid tumour growth. Philos Transact A Math Phys Eng Sci366(1879):3301–18.
52.
MassoudTFGambhirSS. 2003. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev17(5):545–80.
53.
MeadowcroftMDConnorJRSmithMBYangQX. 2009. MRI and histological analysis of beta-amyloid plaques in both human Alzheimer’s disease and APP/PS1 transgenic mice. J Magn Reson Imaging29(5):997–1007.
54.
MielkeRHerholzKGrondMKesslerJHeissWD. 1994. Clinical deterioration in probable Alzheimer’s disease correlates with progressive metabolic impairment of association areas. Dementia5(1):36–41.
55.
MuegglerTBaltesCRudinM. 2009. Molecular neuroimaging in rodents: assessing receptor expression and function. Eur J Neurosci30(10):1860–9.
56.
MuegglerTBaumannDRauschMRudinM. 2001. Bicuculline-induced brain activation in mice detected by functional magnetic resonance imaging. Magn Reson Med46(2):292–8.
57.
MuegglerTBaumannDRauschMStaufenbielMRudinM. 2003. Age-dependent impairment of somatosensory response in the amyloid precursor protein 23 transgenic mouse model of Alzheimer’s disease. J Neurosci23(23):8231–6.
58.
MuegglerTRazouxFRussigHBuehlerAFranklinTBBaltesC, and others. 2010. Mapping of CBV changes in 5-HT(1A) terminal fields by functional MRI in the mouse brain. Eur Neuropsychopharmacol. Epub ahead of print.
59.
MuegglerTSturchler-PierratCBaumannDRauschMStaufenbielMRudinM. 2002. Compromised hemodynamic response in amyloid precursor protein transgenic mice. J Neurosci22(16):7218–24.
60.
MuellerSGWeinerMWThalLJPetersenRCJackCRJagustW, and others. 2005. Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzeimers Dement1(1):55–66.
61.
MulderWJStrijkersGJHabetsJWBleekerEJvan der SchaftDWStormG, and others. 2005. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J. 19(14):2008–10.
62.
NordbergALundqvistHHartvigPLiljaALangstromB. 1995. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains—in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord9(1):21–7.
63.
NordbergARinneJOKadirALångströmB. 2010. The use of PET in Alzheimer disease. Nat Rev Neurol6(2):78–87.
PeneFCourtineECariouAMiraJP. 2009. Toward theragnostics. Crit Care Med 37 Suppl1:S50–8.
66.
PepeuGGiovanniniMG. 2009. Cholinesterase inhibitors and beyond. Curr Alzheimer Res6(2):86–96.
67.
PhelpsME2004. PET—molecular imaging and its biological applications. New York: Springer.
68.
PiperSBahmaniPKlohsJBourayouRBruneckerPMüllerJ, and others. In press. Non-invasive surface-stripping for epifluorescence small animal imaging. Biomed Opt Express.
69.
PodusloJFCurranGLPetersonJAMcCormickDJFauqAHKhanMA, and others. 2004. Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer’s disease amyloid plaques. Biochem43(20):6064–75.
70.
PouyssegurJDayanFMazureNM. 2006. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature441(7092):437–43.
71.
Princz-KranzFLMuegglerTKnoblochMNitschRMRudinM. 2010. Vascular response to acetazolamide decreases as a function of age in the arcAbeta mouse model of cerebral amyloidosis. Neurobiol Dis40(1):284–92.
72.
RanCXuXRaymondSBFerraraBJNealKBacskaiBJ, and others. 2009. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-β deposits. J Am Chem Soc131(42):15257–61.
73.
RauschMHiestandPBaumannDCannetCRudinM. 2003. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med50(2):309–14.
74.
RaymondSBSkochJHillsIDNesterovEESwagerTMBacskaiBJ. 2008. Smart optical probes for near-infrared fluorescence imaging of Alzheimer’s disease pathology. Eur J Nucl Med Mol Imaging 35 Suppl1:S93–8.
75.
ReeseTBjelkeBPorszaszRBaumannDBochelenDSauterA, and others. 2000. Regional brain activation by bicuculline visualized by functional magnetic resonance imaging: time-resolved assessment of bicuculline-induced changes in local cerebral blood volume using an intravascular contrast agent. NMR Biomed13(1):43–9.
76.
ReivichMKuhlDWolfAGreenbergJPhelpsMIdoT, and others. 1979. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res44(1):127–37.
77.
RidhaBHBarnesJBartlettJWGodboltAPeppleTRossorMN, and others. 2006. Tracking atrophy progression in familial Alzheimer’s disease: a serial MRI study. Lancet Neurol5(10):828–34.
78.
RinneJOBrooksDJRossorMNFoxNCBullockRKlunkWE, and others. 2010. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol9(4):363–72.
79.
RinneJOSahlbergNRuottinenHNagrenKLehikoinenO. 1998. Striatal uptake of the dopamine reuptake ligand [11C]beta-CFT is reduced in Alzheimer’s disease assessed by positron emission tomography. Neurology50(1):152–6.
80.
RudinM. 2005. Molecular imaging—basic principles and application in biomedical research. London: Imperial College Press.
81.
RudinM. 2008. Noninvasive imaging of receptor function: signal transduction pathways and physiological readouts. Curr Opin Drug Discov Dev11(5):606–15.
82.
RudinMWeisslederR. 2003. Molecular imaging in drug discovery and development. Nat Rev Drug Discov2(2):123–31.
83.
SchwarzAGozziAReeseTBertaniSCrestanVHaganJ, and others. 2004. Selective dopamine D(3) receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brain. Synapse54(1):1–10.
84.
SchwarzAJGozziAReeseTBifoneA. 2007a. Functional connectivity in the pharmacologically activated brain: resolving networks of correlated responses to d-amphetamine. Magn Reson Med57(4):704–13.
85.
SchwarzAJGozziAReeseTHeidbrederCABifoneA. 2007b. Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d-amphetamine modified by selective dopamine D3 receptor antagonist SB277011A. Magn Reson Imaging25(6):811–20.
86.
SeabJPJagustWJWongSTRoosMSReedBRBudingerTF. 1988. Quantitative NMR measurements of hippocampal atrophy in Alzheimer’s disease. Magn Reson Med8(2):200–8.
87.
SemenzaGL. 2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer3(10):721–32.
88.
ShanerNCSteinbachPATsienRY. 2005. A guide to choosing fluorescent proteins. Nat Methods2(12):905–9.
89.
ShiFLiuBZhouYYuCJiangT. 2009. Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer’s disease: meta-analyses of MRI studies. Hippocampus19(11):1055–64.
90.
SilvermanDHSMelegaWP. 2004. Molecular imaging of biological processes with PET: evaluating biological bases of cerebral function. In: PhelpsME, editor. PET—molecular imaging and its biological applications. New York: Springer. p 509–83.
91.
StefanovaEWallAAlmkvistONilssonAForsbergALangströmB, and others. 2006. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer’s disease. J Neural Transm113(2):205–18.
92.
TjuvajevJGFinnRWatanabeKJoshiROkuTKennedyJ, and others. 1996. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res56(18):4087–95.
93.
TungCHMahmoodUBredowSWeisslederR. 2000. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res60(17):4953–8.
94.
VennetiSLoprestiBJWangGHamiltonRLMathisCAKlunkWE, and others. 2009. PK11195 labels activated microglia in Alzheimer’s disease and in vivo in a mouse model using PET. Neurobiol Aging30(8):1217–26.
95.
WalkerZCostaDCWalkerRWShawKGacinovicSStevensT, and others. 2002. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry73(2):134–40.
96.
WatsonAWuXBruchezM. 2003. Lighting up cells with quantum dots. Biotechniques34(2):296–303.
97.
WinklerDTBondolfiLHerzigMCJannLCalhounMEWiederholdKH, and others. 2001. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci21(5):1619–27.
98.
WiseRGTraceyI. 2006. The role of fMRI in drug discovery. J Magn Reson Imaging23(6):862–76.
99.
WongDFRosenbergPBZhouYKumarARaymontVRavertHT, and others. 2010. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F 18). J Nucl Med51(6):913–20.
100.
WunderAKlohsJDirnaglU. 2009. Non-invasive visualization of CNS inflammation with nuclear and optical imaging. Neuroscience158(3):1161–73.
101.
YasunoFOtaMKosakaJItoHHiguchiMDoronbekovTK, and others. 2008. Increased binding of peripheral benzodiazepine receptor in Alzheimer’s disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry64(10):835–41.
102.
YoffeAD. 2001. Semiconductor quantum dots and related systems: electronic, optical, luminescence and related properties of low dimensional systems. Adv Phys50:1–208.
